Interleukin Genetics to Present at 2008 BIO International ...(that develops preventive consumer produc...)

Date:6/10/2008

that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com .

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report
'/>"/>

SOURCE Interleukin Genetics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
8. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)